Viveve Medical : Current report filing

<_ix3a_header><_ix3a_hidden><_ix3a_nonnumeric contextref="d20228K" name="dei:AmendmentFlag"> false <_ix3a_nonnumeric contextref="d20228K" name="dei:EntityCentralIndexKey">0000879682 <_ix3a_references><_link3a_schemaref _xlink3a_href="vive-20220922.xsd" _xlink3a_type="simple"><_ix3a_resources><_xbrli3a_context id="d20228K"><_xbrli3a_entity><_xbrli3a_identifier scheme="http://www.sec.gov/CIK"> 0000879682 <_xbrli3a_period><_xbrli3a_startdate> 2022-09-22 <_xbrli3a_enddate>2022-09-22

UNITED STATES SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

FORM <_ix3a_nonnumeric contextref="d20228K" name="dei:DocumentType">8-K

CURRENT REPORT

Pursuant to Section13 or 15(d) of the

Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): <_ix3a_nonnumeric contextref="d20228K" format="ixt:datemonthdayyearen" name="dei:DocumentPeriodEndDate">September 22, 2022

<_ix3a_nonnumeric contextref="d20228K" name="dei:EntityRegistrantName">VIVEVE MEDICAL, INC.

(Exact name of registrant as specified in its charter)

<_ix3a_nonnumeric contextref="d20228K" format="ixt-sec:stateprovnameen" name="dei:EntityIncorporationStateCountryCode">Delaware		<_ix3a_nonnumeric contextref="d20228K" name="dei:EntityFileNumber">1-11388		<_ix3a_nonnumeric contextref="d20228K" name="dei:EntityTaxIdentificationNumber">04-3153858
(State or other jurisdiction of incorporation)		(Commission File Number)		(I.R.S. Employer Identification No.)

<_ix3a_nonnumeric contextref="d20228K" name="dei:EntityAddressAddressLine1">345 Inverness Drive South, Building B, Suite 250 <_ix3a_nonnumeric contextref="d20228K" name="dei:EntityAddressCityOrTown">Englewood, <_ix3a_nonnumeric contextref="d20228K" format="ixt-sec:stateprovnameen" name="dei:EntityAddressStateOrProvince">Colorado		<_ix3a_nonnumeric contextref="d20228K" name="dei:EntityAddressPostalZipCode">80112
(Address of principal executive offices)		(Zip Code)

Registrant's telephone number, including area code: (<_ix3a_nonnumeric contextref="d20228K" name="dei:CityAreaCode">720) <_ix3a_nonnumeric contextref="d20228K" name="dei:LocalPhoneNumber">696-8100

Securities registered pursuant to Section 12(b) of the Act:

Title of each class	Trading symbol(s)	Name of each exchange on which registered
<_ix3a_nonnumeric contextref="d20228K" name="dei:Security12bTitle">Common Stock	<_ix3a_nonnumeric contextref="d20228K" name="dei:TradingSymbol">VIVE	<_ix3a_nonnumeric contextref="d20228K" format="ixt-sec:exchnameen" name="dei:SecurityExchangeName">Nasdaq Capital Market

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

<_ix3a_nonnumeric contextref="d20228K" format="ixt-sec:boolballotbox" name="dei:WrittenCommunications">☐

Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

<_ix3a_nonnumeric contextref="d20228K" format="ixt-sec:boolballotbox" name="dei:SolicitingMaterial">☐

Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

<_ix3a_nonnumeric contextref="d20228K" format="ixt-sec:boolballotbox" name="dei:PreCommencementTenderOffer">☐

Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

<_ix3a_nonnumeric contextref="d20228K" format="ixt-sec:boolballotbox" name="dei:PreCommencementIssuerTenderOffer">☐

Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 or Rule 12b-2 of the Securities Exchange Act of 1934.

Emerging growth company <_ix3a_nonnumeric contextref="d20228K" format="ixt-sec:boolballotbox" name="dei:EntityEmergingGrowthCompany">☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Item7.01.

Regulation FD Disclosure.

On September 22, 2022, the Company issued a press release entitled "Viveve to Participate in Ladenburg Thalmann Healthcare Conference". A copy of the Company's press release is furnished herewith as Exhibit 99.1 to this Current Report on Form 8-K and incorporated herein by reference.

The information in Item 7.01 of this Current Report on Form 8-K, including Exhibit 99.1 attached hereto, is being furnished and shall not be deemed "filed" for the purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), or otherwise subject to the liabilities of that Section, nor shall it be deemed subject to the requirements of amended Item 10 of Regulation S-K, nor shall it be deemed incorporated by reference into any filing of the Company under the Securities Act of 1933, as amended, or the Exchange Act, whether made before or after the date hereof, regardless of any general incorporation language in such filing. The furnishing of this information hereby shall not be deemed an admission as to the materiality of any such information.

Item9.01.

Financial Statements and Exhibits.

(d) Exhibits

Exhibit No.		Description
99.1		Press Release issued by the Company on September 22, 2022, furnished herewith.
104		Cover Page Interactive Data File (embedded within the Inline XBRL document)

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

Date: September 22, 2022	Viveve Medical, Inc.
	By:	/s/ Scott Durbin
		Scott Durbin
		Chief Executive Officer